TABLE 2.
Pharmacokinetic parameters of rhG-CSF in cancer patients at neutropenia and neutrophilia
| Patient no. | Neutropenia
|
Neutrophilia
|
||||||
|---|---|---|---|---|---|---|---|---|
| AUC0–∞ (μg · h/ml) | t1/2 (h) | CL (ml/h) | Vd (ml) | AUC0–∞ (μg · h/ml) | t1/2 (h) | CL (ml/h) | Vd (ml) | |
| 1 | 0.37 | 2.61 | 1,080 | 3,771 | 0.23 | 1.89 | 1,696 | 4,774 |
| 2 | 0.37 | 4.79 | 836 | 5,174 | 0.18 | 1.17 | 1,383 | 3,273 |
| 3 | 0.49 | 2.68 | 700 | 2,627 | 0.19 | 1.94 | 1,504 | 4,449 |
| 4 | 0.25 | 2.38 | 1,398 | 3,189 | 0.13 | 0.73 | 1,582 | 2,466 |
| 5 | 0.35 | 4.09 | 961 | 4,619 | 0.19 | 1.46 | 1,321 | 3,072 |
| Mean ± SD | 0.37 ± 0.09 | 3.31 ± 1.07 | 995 ± 266 | 3,876 ± 1,034 | 0.18 ± 0.04a | 1.44 ± 0.51b | 1,497 ± 132a | 3,607 ± 971 |
a
P < 0.01 versus neutropenia value.
b
P < 0.05 versus neutropenia value.